BuTrans in moderate chronic pain

BuTrans (buprenorphine) patches are now indicated in the management of non-malignant moderate chronic pain when an opioid is necessary for obtaining adequate analgesia.

The lowest strength (5 microgram/hr) patch should be used initially and the dose may be increased after three days; when the maximum effect of a given dose is established. The dose should be titrated according to the patient's analgesic response to the BuTrans patch and the need for supplemental pain relief.

View BuTrans drug record

Further information: Napp

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases